NCT05124483View on ClinicalTrials.gov

Anti-COVID19 VaccinaTion AKS-452 BOOSTER (ACT-BOOSTER Study)

PHASE2UnknownINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

April 21, 2022

Primary Completion Date

July 1, 2022

Study Completion Date

February 1, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

AKS-452X

subcutaneous injection of 90 µg AKS-452X

Trial Locations (1)

9700 RB

RECRUITING

University Medical Center Groningen, Groningen

Sponsors

Collaborators (1)

PRA Health Sciences
All Listed Sponsors
collaborator

TRACER Europe BV

INDUSTRY

collaborator

PRA Health Sciences

INDUSTRY

lead

University Medical Center Groningen

OTHER